Table 3. Comparison of baseline with month 12 outcomes for 0.5 vs 2.0 mg dose of ranibizumab by two-way ANOVA (N=36).
Outcome variable | Dose (mg) | Baseline mean (SD) | Month 12 mean (SD) | P-value between regimens | P-value within regimen |
---|---|---|---|---|---|
PED height, μm | 0.5 | 402.96 (168.10) | 235.36 (153.82) | 0.95 | <0.001 |
2.0 | 438.30 (183.84) | 193.24 (154.52) | |||
Central 1-mm thickness, μm | 0.5 | 311.00 (96.68) | 200.38 (48.70) | 0.70 | <0.001 |
2.0 | 304.61 (77.78) | 221.52 (60.41) | |||
PED SA (mm2) | 0.5 | 10.98 (3.12) | 7.94 (5.00) | 0.35 | <0.001 |
2.0 | 10.10 (7.29) | 5.53 (4.48) | |||
PED GLD, μm | 0.5 | 4256.83 (445.18) | 3541.71 (1061.11) | 0.22 | <0.001 |
2.0 | 3982.64 (1431.51) | 2875.82 (1456.70) | |||
CNV SA (mm2) | 0.5 | 4.08 (3.86) | 2.32 (2.91) | 0.06 | 0.001 |
2.0 | 1.65 (1.67) | 0.70 (0.46) | |||
CNV GLD, μm | 0.5 | 2599.32 (1468.19) | 1811.08 (1367.71) | 0.11 | 0.044 |
2.0 | 1581.76 (775.25) | 1350.51 (1011.17) | |||
Contrast sensitivity | 0.5 | 25.73 (4.50) | 25.18 (9.79) | 0.54 | 0.75 |
2.0 | 26.38 (6.5) | 27.57 (7.09) | |||
BCVA LogMar | 0.5 | 0.64 (0.21) | 0.53 (0.44) | 0.10 | 0.05 |
2.0 | 0.52 (0.15) | 0.41 (0.29) |
Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; GLD, greatest linear diameter; LogMar, logarithm10 reciprocal of snellen visual acuity equivalent; PED, pigment epithelial detachment; SA, surface area; SD, standard deviation.